Begin main content


Last Updated: January 15, 2016
Result type: Reports
Project Number: SR0474-000
Product Line: Common Drug Review

Generic Name: ticagrelor

Brand Name: Brilinta

Manufacturer: AstraZeneca Canada Inc

Indications: Prevention of atherothrombotic events with history of myocardial infarction

Submission Type: New Indication

Project Status: Active

Date Recommendation Issued: August 25, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions